Satellos Bioscience Inc T.MSCL

Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

<< Previous

Bullboard Posts

Next >>

Post by bmreedon Oct 24, 2022 10:30am

346 Views

Post# 35043469

Video Recap - $MSCL CEO Frank Gleeson & CTO Phil Lambert

Webinar Recap: Satellos Bioscience (MSCL) w CEO Frank Gleeson and CTO Phil Lambert - Pitch, Deep Dive and Q&A - https://youtu.be/n2DKT55G1pk

CEO Frank Gleeson and CTO Phil Lambert discuss the progress and evolution in the company's new approach to treating various forms of muscular dystrophy.